| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/07/2009 | US7514443 pyrazolo- and imidazo-pyrimidine derivatives; for anxiety and pain, neurodegenerative disorders; 8-Pyridin-4-yl-4-trifluoromethyl-2-(4-trifluoromethyl-phenyl)-imidazo[1,5-a]pyrimidine |
| 04/07/2009 | US7514442 Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 04/07/2009 | US7514429 Benzoxazinone-derived compounds, their preparation and use as medicaments |
| 04/07/2009 | US7514426 Substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives |
| 04/07/2009 | US7514424 schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, visceral pain, neurogenic inflammation, asthma, micturition disorders such as urinary incontinence and nociception; reductive hydrogenation |
| 04/07/2009 | US7514422 To treat obesity, schizophrenia, anxiety, depression, alcoholism; using 3-benoazepine compounds like 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (lorcaserin); serotonin 2c receptor agonists |
| 04/07/2009 | US7514398 Growth factor complex |
| 04/07/2009 | US7514239 Nucleotide sequences coding polypeptide for use in the treatment of preferential glandular disorders |
| 04/07/2009 | US7514225 detecting drugs that inhibits the binding of macrophage migration inhibitory factor (MIF) to an antimacrophage migration inhibitor factor monoclonal or polyclonal antibody; drug screening |
| 04/07/2009 | US7514208 Methods for identifying modulators of cyclic nucleotide-gated cation channels |
| 04/07/2009 | US7514107 Treatment of diseases involving defective gap junctional communication |
| 04/07/2009 | US7514104 Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory |
| 04/07/2009 | US7514100 Controlled release hydrocodone formulations |
| 04/07/2009 | CA2527366C A method of promoting sleep using topical administration of vasoactive agents |
| 04/07/2009 | CA2498291C Diazabicyclic compounds useful in the treatment of cns and other disorders |
| 04/07/2009 | CA2493633C Kinase inhibitors |
| 04/07/2009 | CA2485656C Device for the transdermal administration of a rotigotine base |
| 04/07/2009 | CA2463294C Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 04/07/2009 | CA2416706C Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient |
| 04/07/2009 | CA2415890C N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 04/07/2009 | CA2413190C Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 04/07/2009 | CA2407345C 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol |
| 04/07/2009 | CA2390116C Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 04/07/2009 | CA2387888C Local prevention or amelioration of pain from surgically closed wounds |
| 04/07/2009 | CA2362833C Phenylalaninol derivatives |
| 04/07/2009 | CA2361998C Aromatic heterocyclic compounds as anti-inflammatory agents |
| 04/07/2009 | CA2341991C Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists |
| 04/07/2009 | CA2339253C Inhibitors of p38 |
| 04/07/2009 | CA2312856C Use of ginkgo biloba extracts for preparing a medicine |
| 04/07/2009 | CA2297097C Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
| 04/07/2009 | CA2294950C Levobupivacaine and its use |
| 04/07/2009 | CA2276278C Amine compounds, their production and use |
| 04/07/2009 | CA2256633C Selected derivatives of k-252a |
| 04/07/2009 | CA2174494C Benzofurans |
| 04/07/2009 | CA2168570C Use of growth hormone for increasement of concentration of gh, igf-i and igfbp-3 in cerebrospinal fluid |
| 04/02/2009 | WO2009042906A1 Compositions and methods for camkii inhibitors and uses thereof |
| 04/02/2009 | WO2009042892A1 Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| 04/02/2009 | WO2009042733A1 Solids forms of ( s) -ethyl 2-amin0-3- (4- (2 -amino- 6- ( (r) -1- (4-chl0r0-2- o-methyl-ih-pyrazol- 1-yl) phenyl) -2, 2, 2-trifluorethoxy) -pyrimidin-4-yl) phenyl) propanoate |
| 04/02/2009 | WO2009042694A1 (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating |
| 04/02/2009 | WO2009042200A1 Solid forms comprising 3-(2,5-dimethyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same |
| 04/02/2009 | WO2009041902A1 Prion protein derived cell penetrating peptides and their uses |
| 04/02/2009 | WO2009041714A1 External preparation for free radical diseases |
| 04/02/2009 | WO2009041700A1 Pharmaceutical composition |
| 04/02/2009 | WO2009041567A1 Diaryl ketimine derivative having antagonistic activity on melanin-concentrating hormone receptor |
| 04/02/2009 | WO2009041521A1 Quinolone derivative |
| 04/02/2009 | WO2009041453A1 Bicyclic γ-amino acid derivative |
| 04/02/2009 | WO2009041026A1 Cxcl10 production inhibitor |
| 04/02/2009 | WO2009040552A2 Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof |
| 04/02/2009 | WO2009040423A1 Use of tocopherol derivatives as inhibitors of the notch signalling pathway |
| 04/02/2009 | WO2009040290A1 Quinoline derivatives as 5ht5a receptor antagonists |
| 04/02/2009 | WO2009040089A2 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents |
| 04/02/2009 | WO2009040088A1 Use of peptide kvlpvpq as a therapeutic agent |
| 04/02/2009 | WO2009040087A2 Therapeutic use of peptide yglf and combination with kvlpvpq |
| 04/02/2009 | WO2009040086A2 Use of salusin-alpha as a therapeutic agent |
| 04/02/2009 | WO2009040085A2 Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s) |
| 04/02/2009 | WO2009040084A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040083A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040073A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040072A2 Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040071A2 Use of cyclo-rgdfv and optionally angiotensin i as therapeutic agents in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040070A2 Use of helodermin as a therapeutic agent |
| 04/02/2009 | WO2009040068A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040067A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040051A2 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
| 04/02/2009 | WO2009040050A2 Use of calcitonin as anti-angiogenic agent |
| 04/02/2009 | WO2009040049A2 Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents |
| 04/02/2009 | WO2009040048A2 Use of the c-reactive peptide as a therapeutic agent |
| 04/02/2009 | WO2009040047A2 Therapeutic uses of ghrelin and combinations with stresscopin |
| 04/02/2009 | WO2009040046A2 Use of stresscopin-related peptide as a therapeutic agent |
| 04/02/2009 | WO2009040045A2 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents |
| 04/02/2009 | WO2009040036A2 Use of a galanin peptide as a therapeutic agent |
| 04/02/2009 | WO2009040035A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040034A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040033A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040032A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040031A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040030A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040029A2 Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040028A2 Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040027A1 Use of the peptide stresscopin as a therapeutic agent |
| 04/02/2009 | WO2009040025A2 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent |
| 04/02/2009 | WO2009040024A2 Use of bim-23127 and optionally urodilatin as therapeutic agents eg for the treatment of m. tuberculosis infections |
| 04/02/2009 | WO2009040023A2 Use of galnon as a therapeutic agent |
| 04/02/2009 | WO2009040022A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040021A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040020A1 Amylin as a therapeutic agent |
| 04/02/2009 | WO2009040019A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040018A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040017A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040006A1 Spantide for therapeutic uses |
| 04/02/2009 | WO2009040005A2 Use of the peptide rfmwmr as a therapeutic agent |
| 04/02/2009 | WO2009040004A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039996A2 Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent |
| 04/02/2009 | WO2009039995A1 Big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039994A1 Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039993A2 Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039992A2 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039991A2 Use of aviptadil as a therapeutic agent |
| 04/02/2009 | WO2009039990A2 Use of icam peptide as a therapeutic agent |
| 04/02/2009 | WO2009039989A1 Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent |